| The chemical evolution of oligonucleotide therapies of clinical utility A Khvorova, JK Watts Nature biotechnology 35 (3), 238-248, 2017 | 1153 | 2017 |
| Silencing disease genes in the laboratory and the clinic JK Watts, DR Corey The Journal of pathology 226 (2), 365-379, 2012 | 580* | 2012 |
| Chemically modified siRNA: tools and applications JK Watts, GF Deleavey, MJ Damha Drug discovery today 13 (19-20), 842-855, 2008 | 563 | 2008 |
| Enhancer RNA facilitates NELF release from immediate early genes K Schaukowitch, JY Joo, X Liu, JK Watts, C Martinez, TK Kim Molecular cell 56 (1), 29-42, 2014 | 479 | 2014 |
| RNA therapeutics on the rise F Wang, T Zuroske, JK Watts Nature Reviews Drug Discovery 19, 441-442, 2020 | 256 | 2020 |
| Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide H Tran, MP Moazami, H Yang, D McKenna-Yasek, CL Douthwright, ... Nature medicine 28 (1), 117-124, 2022 | 148 | 2022 |
| Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing GF Deleavey, JK Watts, T Alain, F Robert, A Kalota, V Aishwarya, ... Nucleic acids research 38 (13), 4547-4557, 2010 | 131 | 2010 |
| Oligonucleotide therapeutics: chemistry, delivery and clinical progress VK Sharma, JK Watts Future medicinal chemistry 7 (16), 2221-2242, 2015 | 127 | 2015 |
| Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing A Mir, JF Alterman, MR Hassler, AJ Debacker, E Hudgens, D Echeverria, ... Nature Communications 9, 2641, 2018 | 116 | 2018 |
| The NIH somatic cell genome editing program K Saha, EJ Sontheimer, PJ Brooks, MR Dwinell, CA Gersbach, DR Liu, ... Nature 592 (7853), 195-204, 2021 | 113 | 2021 |
| Energetically important C− H··· F− C pseudohydrogen bonding in water: evidence and application to rational design of oligonucleotides with high binding affinity MY Anzahaee, JK Watts, NR Alla, AW Nicholson, MJ Damha Journal of the American Chemical Society 133 (4), 728-731, 2011 | 113 | 2011 |
| 2′-Fluoro-4′-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity JK Watts, N Choubdar, K Sadalapure, F Robert, AS Wahba, J Pelletier, ... Nucleic acids research 35 (5), 1441-1451, 2007 | 112 | 2007 |
| Differential stability of 2′ F-ANA• RNA and ANA• RNA hybrid duplexes: roles of structure, pseudohydrogen bonding, hydration, ion uptake and flexibility JK Watts, N Martín-Pintado, I Gomez-Pinto, J Schwartzentruber, G Portella, ... Nucleic acids research 38 (7), 2498-2511, 2010 | 94 | 2010 |
| Chemical modification of siRNA GF Deleavey, JK Watts, MJ Damha Current Protocols in Nucleic Acid Chemistry 39 (1), 16.3. 1-16.3. 22, 2009 | 93 | 2009 |
| Generation of novel hybrid aptamer–molecularly imprinted polymeric nanoparticles A Poma, H Brahmbhatt, HM Pendergraff, JK Watts, NW Turner Advanced Materials 27 (4), 750-758, 2015 | 92 | 2015 |
| Clinical status of duplex RNA JK Watts, DR Corey Bioorganic & medicinal chemistry letters 20 (11), 3203-3207, 2010 | 90 | 2010 |
| 2′ F-Arabinonucleic acids (2′ F-ANA)—History, properties, and new frontiers JK Watts, MJ Damha Canadian Journal of Chemistry 86 (7), 641-656, 2008 | 83 | 2008 |
| Studies on the hydrolytic stability of 2′-fluoroarabinonucleic acid (2′ F-ANA) JK Watts, A Katolik, J Viladoms, MJ Damha Organic & Biomolecular Chemistry 7 (9), 1904-1910, 2009 | 79 | 2009 |
| Oligonucleotides targeting TCF4 triplet repeat expansion inhibit RNA foci and mis-splicing in Fuchs’ dystrophy J Hu, Z Rong, X Gong, Z Zhou, VK Sharma, C Xing, JK Watts, DR Corey, ... Human molecular genetics 27 (6), 1015-1026, 2018 | 71 | 2018 |
| Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs J Hu, KT Gagnon, J Liu, JK Watts, J Syeda-Nawaz, CF Bennett, ... Walter de Gruyter 392 (4), 315-325, 2011 | 66 | 2011 |
Anastasia KhvorovaUMASS Medical School在 umassmed.edu 的电子邮件经过验证